Original Article Bezaﬁbrate ameliorates diabetes reduced steatosis improved hepatic insulin sensitivity diabetic TallyHo mice Andras Franko 123 Susanne Neschen 19 Jan Rozman 13 Birgit Rathkolb 134 Michaela Aichler 5 Annette Feuchtinger 5 Laura Brachthäuser 6 Frauke Neff 6 Marketa Kovarova 2 Eckhard Wolf 4 Helmut Fuchs 1 HansUlrich Häring 237 Andreas Peter 237 Martin Hrabcid2e Angelis 138 ABSTRACT Objective Recently shown Bezaﬁbrate BEZ panPPAR peroxisome proliferatoractivated receptor activator ameliorated diabetes insulin deﬁcient streptozotocin treated diabetic mice In order study BEZ improve glucose metabolism mouse model fatty liver type 2 diabetes drug applied TallyHo mice Methods TallyHo mice divided early ED late LD diabetes progression group groups treated 05 BEZ BEZ group standard diet SD group 8 weeks We analyzed plasma parameters pancreatic betacell morphology mass glucose metabolism BEZtreated control mice Furthermore liver fat content composition hepatic gluconeogenesis mitochondrial mass determined Results Plasma lipid glucose levels markedly reduced BEZ treatment accompanied elevated insulin sensitivity index glucose tolerance respectively BEZ increased islet area pancreas Furthermore BEZ treatment improved energy expenditure metabolic ﬂexibility In liver BEZ ameliorated steatosis modiﬁed lipid composition increased mitochondrial mass accompanied reduced hepatic gluconeogenesis Conclusions Our data showed BEZ ameliorates diabetes probably reduced steatosis enhanced hepatic mitochondrial mass improved metabolic ﬂexibility elevated hepatic insulin sensitivity TallyHo mice suggesting BEZ treatment beneﬁcial patients NAFLD impaired glucose metabolism cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 Keywords Bezaﬁbrate Glucose metabolism Insulin resistance Lipid metabolism NAFLD 1 INTRODUCTION Bezaﬁbrate BEZ member ﬁbrate group possesses unique feature activating known peroxisome proliferator activated receptors PPARs PPARa PPARg PPARbd 1 PPARs transcription factors regulating crucial genes involved fatty acid metabolism insulin sensitivity 1 BEZ primarily treat patients hyperlipidemia 2 shown improve glucose metabolism rodents 3 humans 4 Recently shown BEZ improves glucose metabolism diabetes insulin deﬁcient streptozotocin treated mice 5 To study BEZ ameliorate conditions associated fatty 1Institute Experimental Genetics Helmholtz Zentrum München Ingolstädter Landstraße 1 85764 Neuherberg Germany 2Department Internal Medicine IV Division Endocrinology Diabetology Angiology Nephrology Clinical Chemistry University Hospital Tübingen OtfriedMüllerStr 10 72076 Tübingen Germany 3German Center Diabetes Research DZD eV Ingolstädter Landstraße 1 85764 Neuherberg Germany 4Institute Molecular Animal Breeding Biotechnology LudwigMaximilians UniversitätMünchen Hackerstr 27 85764 Oberschleißheim Germany 5Research Unit Analytical Pathology Helmholtz Zentrum München Ingolstädter Landstraße 1 85764 Neuherberg Germany 6Institute Pathology Helmholtz Zentrum München Ingolstädter Landstraße 1 85764 Neuherberg Germany 7Institute Diabetes Research Metabolic Diseases Helmholtz Centre Munich University Tübingen OtfriedMüllerStr 10 72076 Tübingen Germany 8Center Life Food Sciences Weihenstephan Technische Universität München Alte Akademie 8 85354 Freising Germany 9 Current address SanoﬁAventis Deutschland GmbH RD Diabetes Research Translational Medicine Industriepark Hoechst 65926 Frankfurt Main Germany Corresponding author Department Internal Medicine IV Division Endocrinology Diabetology Angiology Nephrology Clinical Chemistry University Hospital Tübingen OtfriedMüllerStr 10 72076 Tübingen Germany Fax þ49 7071 29 4690 Email andrasfrankomedunituebingende A Franko Corresponding author Institute Experimental Genetics Helmholtz Zentrum München GmbH Ingolstädter Landstraße 1 85764 Neuherberg Germany Fax þ49 89 3187 3500 Email hrabehelmholtzmuenchende M Hrabcid2e Angelis Abbreviations BEZ Bezaﬁbrate BG blood glucose ED early onset diabetes EM electron microscopy HOMAIR homeostatic model assessment insulin resistance FA fatty acid LD late onset diabetes NAFLD nonalcoholic fatty liver disease NEFA nonesteriﬁed fatty acid PPAR peroxisome proliferatoractivated receptor qNMR quantitative nuclear magnetic resonance RER respiratory exchange ratios SD standard diet T2D type 2 diabetes TG triglyceride Received November 17 2016 cid2 Revision received December 8 2016 cid2 Accepted December 15 2016 cid2 Available online 6 January 2017 httpdxdoiorg101016jmolmet201612007 256 MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom liver type 2 diabetes TallyHo mouse model TallyHo mice described 2001 characterized elevated plasma lipid levels body weight high fat mass steatosis intermediate severe diabetes 67 Compared classical monogenic diabetes models like obob dbdb mice polygenic nature TallyHo mice adds clear beneﬁt models better resembling human disease state T2D 7 Recent studies identiﬁed diabetes loci Tanidd14 Tabw34 act concert promote diabetes male TallyHo mice reduced peripheral glucose uptake enlarged pancreatic islets 8 Our data demonstrated BEZ ameliorates impaired glucose metabolism TallyHo mice decreased hepatic fat content suppressed hepatic gluconeogenesis association increased mitochondrial mass elevated metabolic ﬂexibility infusion rate plasma 33Hglucose speciﬁc activity The EndoRa insulinstimulated conditions determined subtracting Glucose Infusion Rate GINF rate disappearance Rd Tissue 214Cdeoxyglucose6phosphate extracted glucose uptake rates Rg calculated previously described 11 Whole body glycolysis rates calculated increase plasma 3H2O concentration referring difference 3H counts drying divided speciﬁc activity plasma 33H glucose plasma 3H2O concentration Immunoﬂuorescence staining 24 Pancreata ﬁxed 4 paraformaldehyde cryosections stained antiinsulin antiglucagon antibodies described previously 5 2 MATERIALS AND METHODS 21 Materials All chemicals purchased SigmaeAldrich Germany stated 22 Animal studies TallyHo mice purchased Jackson Laboratories bred animal facility Only male mice study mice received standard diet SD RMH Ssniff Germany supplemented 05 ww Bezaﬁbrate BEZ B7273 Sigmae Aldrich BEZ groups 8 weeks Animals killed iso ﬂurane overdose dissected tissues prepared stated All data represent samples taken 8 weeks BEZ SD treatment stated All animals received humane care mouse studies approved local government authorities performed according GVSOLAS Society Laboratory Animal Science accordance German Animal Welfare Act Plasma triglyceride TG nonesteriﬁed fatty acid NEFA glycerol glucose Creactive protein CRP levels quantiﬁed AU480 clinical chemistry analyzer Beckman Coulter Germany 9 Blood glucose levels measured tail blood samples point care glucometer Contour Bayer Germany plasma insulin levels determined ELISA MultiSpot electro chemiluminescence Assay System Mesoscale Rockville USA Intraperitoneal glucose tolerance tests performed 7 weeks BEZ treatment 1 gkg glucose tail blood values higher upper limit glucometer 600 mgdl plasma glucose levels determined LabAssay Glucose Kit Wako Richmond USA Homeostatic model assessment insulin resistance HOMAIR value calculated fasting glucose mg dl cid3 fasting insulin mIUml405 Body composition indirect calorimetry studied 5 weeks BEZ treatment described previously 5 23 Euglycemichyperinsulinemic clamps Euglycemichyperinsulinemic clamp studies performed 6e7 weeks BEZ treatment previously published 10 To initiate euglycemichyperinsulinemic clamp continuous insulin infusion cid41 Humulin R Lilly Indianapolis USA started 6 mUkg min continued 120 min Between 90 120 min blood samples collected calculation insulinmediated suppression endogenous glucose appearance rates EndoRa marker hepatic glucose production At 120 min 2deoxyD114Cglucose injected intravenously 370 kBq additional blood samples collected Basal EndoRa calculated ratio 33Hglucose 25 Histochemistry Liver tissues ﬁxed 4 paraformaldehyde parafﬁn sections stained hematoxylin eosin described previously 5 26 Hepatic lipid levels Liver samples homogenized PBS containing 1 Triton X100 TissueLyser Qiagen Hilden Germany Triglyceride TG levels quantiﬁed homogenates ADVIA XPT clinical Siemens Healthcare Diagnostics Eschborn chemistry analyzer Germany Transesteriﬁcation fatty acids quantiﬁcation gas chromatography ﬂame ionization detection performed described previously 12 27 Realtime PCR Mouse livers pulverized liquid nitrogen total RNA prepared RNeasy Mini kit Qiagen cDNA prepared reverse transcription Thermo Fischer Scientiﬁc Waltham USA realtime PCR assays carried LC480 Light Cycler Roche Mannheim Germany Scd1 Scd2 Fasn Gapdh Cs Ndufab1 Cox19 Cpt2 Hadha Rps2 universal probe library Roche Calculations comparative cid4DDCt normalized Gapdh Scd1 Scd2 method 2 Fasn Rps2 Cs Ndufab1 Cox19 Cpt2 Hadha housekeeping genes The applied primer sequences shown Suppl Table 2 28 Transmission electron microscopy Liver quadriceps samples ﬁxed 25 glutaraldehyde 01 M sodium cacodylate buffer analyzed described previously 13 29 Western blot Liver homogenates loaded acrylamide gel western blots performed described earlier 5 abtubulin antibody purchased Cell Signaling Technology Cambridge UK citrate synthase antibody Abcam Cambridge UK secondary antibody purchased Santa Cruz Biotechnology Santa Cruz USA 210 Statistics Statistical evaluations performed GraphPad Prism 607 ANOVA post hoc Holmcid2Sídáks multiple comparison tests calculate statistical signiﬁcance comparing groups tailed unpaired Students tests applied unequal distribution groups compared Statistical signiﬁcance assumed p 005 MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom 257 Original Article Figure 1 Levels blood glucose plasma lipid insulin glucose tolerance test A The ﬁgure represents averages weekly measured blood glucose values values week 9 showed Suppl Figure 1A TallyHo mice split groups according 9 weeks old blood glucose values early onset diabetes ED group 200 mgdl late onset diabetes LD group 200 mgdl BEZ SD feeding started 9 weeks age lasted 8 weeks Standard diet SD BEZ diet BEZ B Plasma nonesteriﬁed fatty acids NEFA C triglyceride TG levels D Fasted blood glucose BG values E Plasma insulin levels F Homeostatic model assessment insulin resistance HOMAIR values G Glucose tolerance test GTT H area curve AUC evaluation Columns represent averages cid5 standard deviations n ¼ 6e12 denotes signiﬁcant differences ED BEZ vs ED SD p 001 p 0001 denotes signiﬁcant differences ED SD vs LD SD p 001 p 0001 xdenotes signiﬁcant differences LD BEZ vs LD SD xxxp 0001 258 MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom 3 RESULTS 31 TallyHo mice TallyHo mice represent polygenic mouse model diabetes mild steatosis insulin resistance However mice display dividual onset diabetes standard diet fast slow pro gressors identiﬁed In order study effect Bezaﬁbrate BEZ different stages diabetes TallyHo mice divided groups 9 weeks age Mice fasting blood glucose 200 mgdl deﬁned late onset diabetes LD group mice blood glucose values 200 mgdl classiﬁed early onset diabetes ED group Figure 1A Thus LD mice represented preventive group studied BEZ protect mice prediabetic stage diabetes progression ED mice served therapeutic group inves tigated BEZ treatment revert established diabetes 32 BEZ ameliorates diabetes reduces plasma lipid levels improves glucose tolerance In order study BEZ beneﬁcial effect prevent development LD group ameliorate T2D ED group TallyHo groups treated 8 weeks BEZ containing diet BEZ group standard diet SD At 9 weeks age ED SD mice showed higher BG levels compared LD SD mice Suppl Figure 1A untreated groups developed diabetes age 17 weeks Figure 1D Compared SD groups BEZ reduced plasma lipid glycerol Figure 1BC Suppl Figure 1B suggesting reduced lipolysis Furthermore level levels plasma glucose glucose measurements CRP inﬂammatory marker tended decrease BEZ treatment Suppl Figure 1C indicating possible amelioration inﬂammatory processes BEZ markedly decreased blood glucose levels measured glucometer Figure 1D veriﬁed assay Suppl Figure 1D Insulin levels lower LD BEZ vs LD SD remained unchanged ED BEZ vs ED SD BEZ groups Figure 1E As consequence HOMAIR values normalized BEZ groups Figure 1F Furthermore BEZ attenuated impaired glucose tolerance TallyHo mice Figure 1GH increasing test Suppl Figure 1EeF These results suggest BEZ improved insulin sensitivity glucose metabolism turn resulted normalization blood glucose levels independently plasma insulin levels tolerance glucose insulin levels 33 BEZ increases betacell mass Next studied pancreatic architecture BEZtreated animals BEZ elevated content insulin producing betacells islets Figure 2AeB increased total insulin area pancreas total islet number Figure 2CD Glucagon area normalized islets higher ED SD group compared LD SD mice total glucagon area remained unchanged Suppl Figure 2 34 BEZ elevates energy expenditure metabolic ﬂexibility BEZ treatment resulted lower body weight LD group opposite effect ED group Figure 3A BEZ increased relative lean decreased fat mass LD mice Figure 3BeC Figure 2 Pancreas architecture A Pancreata stained antiinsulin green antiglucagon red antibodies visualized ﬂuorescence microscopy Cell nuclei stained DAPI blue The white bar represents 50 mm Representative areas shown B Insulin area normalized islet area C total insulin area normalized pancreas area calculated Architect software D Islet number manually counted values normalized total pancreas area Columns represent averages cid5 standard deviations n ¼ 5 denotes signiﬁcant differences ED BEZ vs ED SD p 005 p 001 denotes signiﬁcant differences ED SD vs LD SD p 001 xdenotes signiﬁcant differences LD BEZ vs LD SD xxp 001 MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom 259 Original Article Figure 3 Body composition indirect calorimetry A Body weight B Fat C lean mass measured qNMR Suppl Figure 3AB normalized body weights D Average oxygen consumption normalized body weights E Respiratory exchange ratios RERs calculated dividing carbon dioxide production VCO2 oxygen consumption VO2 Suppl Figure 4AeD The gray rectangle represents 12h dark phase 0time point represents 1 pm F DRER calculated RERmax cid4 RERmin Columns represent averages cid5 standard deviations n ¼ 8e12 denotes signiﬁcant differences ED BEZ vs ED SD p 005 p 001 p 0001 denotes signiﬁcant differences ED SD vs LD SD p 005 p 0001 xdenotes signiﬁcant differences LD BEZ vs LD SD xxp 001 xxxp 0001 Suppl Figure 3AB remained signiﬁcant normalized body weight Suppl Figure 3CD BEZ increased food consumption LD group water intake remained unaltered drug treatment Suppl Figure 3EF BEZ elevated carbon dioxide production ox ygen consumption Suppl Figure 4AeD remained signiﬁ normalized body weight Figure 3D marker energy expenditure Respiratory exchange ratio RER metabolic ﬂexibility assessed delta RER higher BEZ treated animals Figure 3EeF Rearing run distance altered BEZ application Suppl Figure 4EeH These data sug gest improved metabolic ﬂexibility energy expenditure involved beneﬁcial role BEZ 35 BEZ reduces hepatic gluconeogenesis LD mice In order assess BEZ improves hepatic insulin sensitivity performed euglycemichyperinsulinemic clamps LD mice To reach applied insulin dose Figure 4A higher normoglycemia glucose infusion rate needed BEZ group Figure 4B 260 MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom Figure 4 Euglycemichyperinsulinemic clamp A Steady state BG levels clamp B Glucose infusion rate GINF C Endogenous glucose production EGP D Whole body glucose uptake Columns represent averages cid5 standard deviations n ¼ 8 animals xdenotes signiﬁcant differences LD BEZ vs LD SD xp 005 xxxp 0001 suggesting elevated insulin sensitivity Endogenous glucose production EGP mainly consists hepatic gluconeogenesis 14 inhibited groups signiﬁcantly stronger effect BEZ group Figure 4C Glucose ﬂux analysis showed elevated body glucose uptake BEZ group Figure 4D glucose uptake increased M quadriceps epididymal fat tissues Suppl Figure 5A Glucosuria normalized BEZ treatment suggesting loss Suppl Figure 5B These results suggest BEZ improved patic insulin sensitivity reduced gluconeogenesis involved amelioration diabetes absence diabetic glucose urinary 36 BEZ reduces hepatic lipid contents LD mice elevates relative MUFA contents ED mice To study underlying mechanisms improved hepatic gluco neogenesis hepatic lipid content BEZtreated mice assessed Histological staining showed reduced steatosis LD mice BEZ treatment Figure 5A associated reduced total hepatic TG content Figure 5B Since fatty liver key component metabolic syndrome strongly associated insulin resistance 15 data suggest BEZ improves insulin sensitivity LD TallyHo mice possibly reduced hepatic stea tosis Lipotoxic effects FA lipid intermediates counteract insulin signaling effects implicated pathogenesis fatty liver insulin resistance Since chain lengths saturation state major impact lipotoxic actions FA monounsaturated FAs MUFAs beneﬁcial effects patients T2D 16 determined exact FA composition hepatic triglycerides As expected reduced total hepatic TG content Figure 5B TGs normalized liver weight lower LD BEZ animals compared LD SD mice ED SD mice showed lower TGs compared LD SD group Suppl Table 1 The total TG content known inﬂuence relative composition TGs FA lengths saturation state 12 Therefore compared relative FA composition ED BEZ ED SD groups total TG contents comparable Figure 5B BEZ increased relative content C140 C160 FAs decreased C180 C200 FA contents Figure 5C left panel C161 C181 MUFAs markedly increased BEZ treatment Figure 5C middle panel precursor n3 n6 polyunsaturated FAs PUFAs PUFAs decreased Figure 5C right panel Suppl Figure 5CD BEZ elevated total MUFA reduced total PUFA content Figure 5D More importantly compared ED SD group ED BEZ mice showed higher MUFASFA ratio 0614 cid5 0176 vs 0340 cid5 0139 p ¼ 00121 elevated stearoyl cisC161n7C160 CoAdesaturase 0088 cid5 0032 vs 0019 cid5 0012 p ¼ 00003 increased novo lipogenesis index C160C182n6 466 cid5 195 vs 176 cid5 042 p ¼ 00011 In order investigate role SCDs FA synthesis transcript levels Scd1 2 fatty acid synthase FASN studied realtime PCR BEZ elevated mRNA level SCDs FASN Figure 5E These results suggest BEZ creases hepatic lipogenesis SCD activity turn elevates content MUFAs On hand reduced PUFA precursors C183n3 C182n6 PUFAs suggest BEZ elevates FA oxidation activity SCD index MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom 261 Original Article Figure 5 Hepatic lipid content A Hematoxylin eosin staining liver black bar represents 50 mm Representative areas shown B Liver total TG levels C relative liver TG fatty acid FA composition n e number denotes position double bounds counted omega carbon Saturated FA SFA monounsaturated FA MUFA polyunsaturated FA PUFA pre precursor D The relative content total SFA MUFA PUFA TG fraction denoted total FA E ED SD group normalized relative mRNA levels indicated transcripts Scd StearoylCoAdesaturase Fasn fatty acid synthase Columns represent averages cid5 standard deviations A C D E represent n ¼ 4e7 B represents n ¼ 8e9 animals denotes signiﬁcant differences ED BEZ vs ED D p 005 p 001 p 0001 denotes signiﬁcant differences ED SD vs LD SD p 0001 xdenotes signiﬁcant differences LD BEZ vs LD SD xxxp 0001 37 BEZ increases mitochondrial mass TallyHo mice Since mitochondria play crucial role FA oxidation studied mitochondrial mass different approaches Transmission EM revealed higher mitochondrial number BEZ groups compared untreated controls Figure 6AB Citrate synthase CS usually marker mitochondrial mass protein mRNA level CS elevated BEZtreated animals Figure 6CD Suppl Figure 6A Higher transcript levels mitochondrial genes Suppl Figure 6BeE These results indicate BEZ induces mitochondrial biogenesis liver TallyHo mice The elevated mitochondrial mass decreased lipid PUFA precursor content liver LD BEZ mice suggest increased hepatic fatty acid oxidation involved attenuated hepatic gluconeogenesis Moreover BEZ increased hepatic MUFA contents possibly involved amelioration glucose metabolism ED BEZ group Skeletal muscle BEZtreated animals showed normal mitochondrial mass Suppl Figure 7 4 DISCUSSION The major ﬁnding study BEZtreated slow progressor late onset diabetes LD TallyHo mice protected dia betes importantly established diabetes early onset diabetes ED group reverted drug application The anti diabetic potential BEZ reported rodent models T1D 5 T2D 317 patients T2D 41819 Furthermore diabetes prevalence patients coronary artery disease showed impaired glucose tolerance attenuated BEZ application 20 These results indicate BEZ prevent progression prediabetic state clinical diabetes revert established diabetic state rodents humans underlying mechanisms currently poorly understood The antidiabetic effect drug probably attributed insulin sensitizing capacity indicated stronger inhibition endogenous glucose production decreased HOMAIR index Tenenbaum et al reported BEZ treatment efﬁcient prevent increase HOMAIR index year follow patients coronary artery disease 21 Although fenoﬁbrate change HOMAIR patients impaired glucose tolerance diabetes BEZ signiﬁcantly decrease HOMAIR compared placebo group 8 weeks treatment 22 studies reported lower HOMAIR BEZtreated patients 1923 In euglycemichyperinsulinemic clamp experiments insulin stim ulus BEZtreated animals caused negative endogenous glucose production EGP values Negative zero values EGP reported rodent models 10 1424e26 attributed high glucose infusion rate 27 BEZ group big difference insulin sensitivity BEZ SD groups 262 MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom Figure 6 Hepatic mitochondrial mass A Liver mitochondrial mass architecture assessed transmission EM black bar denotes 2 mm Representative areas shown B Mitochondrial number quantiﬁed ﬁve independent regions normalized analyzed area mm2 C Hepatic citrate synthase CS protein level analyzed western blot intensity bands normalized tubulin depicted ratio LD SD group Representative pictures shown Suppl Figure 6A D Hepatic gene expression studied realtime PCR depicted ratio LD SD group CS citrate synthase E Our data demonstrated BEZ improves glucose metabolism TallyHo mice In scheme possible underlying mechanisms observed LD mice depicted probably involved beneﬁcial effects BEZ Columns represent averages cid5 standard deviations AeB represent n ¼ 4 CeD represent n ¼ 7e9 animals denotes signiﬁcant differences ED BEZ vs ED SD p 001 p 0001 xdenotes signiﬁcant differences LD BEZ vs LD SD xp 005 xxxp 0001 Therefore negative values BEZtreated mice assumed correspond zero reported 14 Despite negative EGP values results clearly showed BEZ treatment led pronounced reduction EGP reﬂecting improved hepatic insulin sensitivity There studies reporting insulin sensitivity euglycemichyperinsulinemic clamp experiments patients BEZ treatment showed alteration insulin sensitivity patients high lipid levels 28 diabetes 29 improved insulin sensitivity 3031 These results indicate studies needed investigate role BEZ insulin sensitivity human subjects However dual PPARa PPARd activation recently shown improve hepatic insulin sensitivity patients insulin resistance 32 In contrast low insulin levels BEZtreated mice animals showed increased betacell area compared untreated controls BEZ shown improve islet architecture diabetic mice type 1 diabetes 533 compared PPARa activator fenoﬁ brate PPARg activator rosiglitazone PPAR activator prevented compensatory islet hypertrophy high sucrose high fat diet treated mice 34 pointing unique attribute PPAR MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom 263 Original Article activation directly improve betacell function 35 occur secondary consequence amelioration gluco lipotoxicity Metabolic ﬂexibility assumed ability change substrate oxidation fat carbohydrate malfunction intimately related insulin resistance ectopic lipid accumulation 36 Since mitochondria play crucial role substrate oxidation 37 mito chondrial dysfunction reported skeletal muscle insulin resistant mouse models 38 patients 39 patients type 2 diabetes associated metabolic inﬂexibility 40 Furthermore impaired mitochondrial betaoxidation postu lated contribute hepatic steatosis 41 Therefore elevated mitochondrial mass liver BEZtreated animals involved improved metabolic ﬂexibility In TallyHo mice BEZ elevated respiratory exchange ratio RER reﬂects higher car bohydrate oxidation higher delta RER BEZ treatment indicates better metabolic ﬂexibility BEZ treatment patients PNPLA2 mutation improved metabolic ﬂexibility associated better insulin sensitivity 31 suggesting overall effect BEZ mice humans In addition enhanced energy expenditure observed BEZtreated TallyHo mice postulated beneﬁcial prevention lipid accumulation insulin resistance 42 Compared LD SD animals ED SD mice exhibited decreased hepatic fat content probably attributed long lasting diabetic insulin deﬁcient state diminished insulin level impair fat storage On hand LD SD mice good model non alcoholic fatty liver disease NAFLD showed hepatic steatosis insulin resistance hallmarks NAFLD 43 The precursors PUFAs endogenously synthesized supplied food showed lower hepatic contents BEZ treated animals association reduced content PUFAs These data indicate BEZ elevated FA oxidation conse quence decreased hepatic lipid levels The lower hepatic TG level increased mitochondrial mass observed BEZtreated LD TallyHo mice suggest improved FA metabolism lead lipid intermediates attenuating insulin resistance enhancing inhibitory effect insulin endogenous glucose production Figure 6E In addition reducing lipid levels LD mice BEZ changed fatty acid composition ED mice PPARa knockout mice characterized lower C161n7 fatty acid level hepatic TG fraction compared wildtype controls 44 Thus 57times higher C161n7 level BEZ treatment ED mice suggests PPARa plays important role elevating MUFAs A diet enriched MUFAs shown signiﬁcantly decrease HbA1c plasma glucose levels HOMAIR index patients T2D 16 Thus elevated hepatic MUFAs BEZtreated animals participate ameliorating insulin sensitivity diabetes Stearoyl CoAdesaturase SCD corresponding enzyme responsible production C161n7 C181n9 In BEZ treated ED animals higher mRNA levels SCD isoform elevated SCD activity index observed Since high hepatic SCD1 activity associated low hepatic fat content insulin sensitivity human subjects 45e47 increased SCD activity BEZtreated mice contribute improved hepatic insulin sensitivity Although combined treatment NAFLD obesity T2D intensively studied currently limited drugs available 48 In recent years novel dual PPARa PPARg agonists studied new candidates showed undesirable effects 49 In contrast BEZ 40 years market activates PPARs good safety 20 Recently novel PPARa PPARd activator Elaﬁbranor GFT505 shown beneﬁcial effects improving endogenous glucose production blood glucose levels steatosis patients insulin resistance NASH respectively 3250 These observations data suggest activation PPARs represent good treatment option subjects diabetes NAFLD ACKNOWLEDGEMENTS This work funded German Federal Ministry Education Research German Mouse Clinic Infrafrontier grant 01KX1012 German Center Diabetes Research DZD eV We thank Michael Schulz Moya Wu Anett Seelig Jürgen Schultheib excellent technical assistance CONFLICT OF INTEREST None declared APPENDIX A SUPPLEMENTARY DATA Supplementary data related article httpdxdoiorg101016j molmet201612007 REFERENCES 1 GrygielGorniak B 2014 Peroxisome proliferatoractivated receptors ligands nutritional clinical implicationsea review Nutrition Journal 1317 2 Ohno Y Miyoshi T Noda Y Oe H Toh N Nakamura K et al 2014 Bezaﬁbrate improves postprandial hypertriglyceridemia associated endo thelial dysfunction patients metabolic syndrome randomized crossover study Cardiovascular Diabetology 1371 3 Matsui H Okumura K Kawakami K Hibino M Toki Y Ito T 1997 Improved insulin sensitivity bezaﬁbrate rats relationship fatty acid composition skeletalmuscle triglycerides Diabetes 46348e353 4 Jones IR Swai A Taylor R Miller M Laker MF Alberti KG 1990 Lowering plasma glucose concentrations bezaﬁbrate patients moderately controlled NIDDM Diabetes Care 13855e863 5 Franko A Huypens P Neschen S Irmler M Rozman J Rathkolb B et al 2016 Bezaﬁbrate improves insulin sensitivity metabolic ﬂexibility STZinduced diabetic mice Diabetes 652540e2552 6 Kim JH Sen S Avery CS Simpson E Chandler P Nishina PM et al 2001 Genetic analysis new mouse model noninsulindependent diabetes Genomics 74273e286 7 Leiter EH Strobel M ONeill A Schultz D Schile A Reifsnyder PC 2013 Comparison new mouse models polygenic type 2 diabetes Jackson Laboratory NONcNZO10LtJ TALLYHOJngJ Journal Diabetes Research 2013165327 8 Kim JH Saxton AM 2012 The TALLYHO mouse model human type 2 diabetes Methods Molecular Biology 93375e87 9 Rathkolb B Hans W Prehn C Fuchs H GailusDurner V Aigner B et al 2013 Clinical chemistry laboratory tests mouse plasma serum Current Protocols Mouse Biology 369e100 10 Franko A von KleistRetzow JC Neschen S Wu M Schommers P Bose M et al 2014 Liver adapts mitochondrial function insulin resistant diabetic states mice Journal Hepatology 60816e823 11 Konstantopoulos N Molero JC McGee SL Spolding B Connor T Vries M et al 2012 Methazolamide new hepatic insulin sensitizer lowers blood glucose vivo Diabetes 612146e2154 264 MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom 12 Peter A Kovarova M Nadalin S Cermak T Konigsrainer A Machicao F et al 2014 PNPLA3 variant I148M associated altered hepatic lipid composition humans Diabetologia 572103e2107 13 Franko A Baris OR Bergschneider E von Toerne C Hauck SM Aichler M et al 2013 Efﬁcient isolation pure functional mitochondria mouse tissues automated tissue disruption enrichment antiTOM22 magnetic beads PLoS One 8e82392 14 Choukem SP Gautier JF 2008 How measure hepatic insulin resis tance Diabetes Metabolism 34664e673 15 Stefan N Haring HU 2013 The role hepatokines metabolism Nature Reviews Endocrinology 9144e152 16 Schwingshackl L Strasser B 2012 HighMUFA diets reduce fasting glucose patients type 2 diabetes Annals Nutrition Metabolism 6033e34 17 Jia D Yamamoto M Otani M Otsuki M 2004 Bezaﬁbrate lipids glucose metabolism obese diabetic Otsuka LongEvans Tokushima fatty rats Metabolism 53405e413 18 Wahl P Hasslacher C Lang PD Vollmar J 1978 Lipidlowering effect bezaﬁbrate patients diabetes mellitus hyperlipidaemia authors transl Deutsche Medizinische Wochenschrift 1031233e1237 19 Fukushima M Taniguchi A Sakai M Doi K Nagata I Nagasaka S et al 2000 Effect bezaﬁbrate insulin sensitivity nonobese Japanese type 2 diabetic patients Diabetes Care 23259 20 Tenenbaum A Motro M Fisman EZ Schwammenthal E Adler Y Goldenberg I et al 2004 Peroxisome proliferatoractivated receptor ligand bezaﬁbrate prevention type 2 diabetes mellitus patients coronary artery disease Circulation 1092197e2202 21 Tenenbaum A Fisman EZ Boyko V Benderly M Tanne D Haim M et al 2006 Attenuation progression insulin resistance patients coronary artery disease bezaﬁbrate Archives Internal Medicine 166 737e741 22 Noguchi T Kobayashi J Yagi K Nohara A Yamaaki N Sugihara M et al 2011 Comparison effects bezaﬁbrate fenoﬁbrate circulating proprotein convertase subtilisinkexin type 9 adipocytokine levels dyslipidemic subjects impaired glucose tolerance type 2 diabetes mellitus results crossover study Atherosclerosis 217165e170 23 Jonkers IJ Mohrschladt MF Westendorp RG van der Laarse A Smelt AH 2002 Severe hypertriglyceridemia insulin resistance associated systemic inﬂammation reversal bezaﬁbrate therapy randomized controlled trial American Journal Medicine 112275e280 24 Bonner JS Lantier L Hocking KM Kang L Owolabi M James FD et al 2013 Relaxin treatment reverses insulin resistance mice fed high fat diet Diabetes 623251e3260 25 Wang HY Ducommun S Quan C Xie B Li M Wasserman DH et al 2013 AS160 deﬁciency causes wholebody insulin resistance composite effects multiple tissues Biochemical Journal 449479e489 26 Brand CL Sturis J Gotfredsen CF Fleckner J Fledelius C Hansen BF et al 2003 Dual PPARalphagamma activation provides enhanced improvement insulin sensitivity glycemic control ZDF rats American Journal Physiology Endocrinology Metabolism 284E841e E854 27 Ayala JE Samuel VT Morton GJ Obici S Croniger CM Shulman GI et al 2010 Standard operating procedures describing performing metabolic tests glucose homeostasis mice Disease Models Mecha nisms 3525e534 28 Karhapaa P Uusitupa M Voutilainen E Laakso M 1992 Effects bezaﬁbrate insulin sensitivity glucose tolerance subjects combined hyperlipidemia Clinical Pharmacology Therapeutics 52620e 626 29 Riccardi G Genovese S Saldalamacchia G Patti L Marotta G Postiglione A et al 1989 Effects bezaﬁbrate insulin secretion peripheral insulin sensitivity hyperlipidemic patients dia betes Atherosclerosis 75175e181 30 Shiochi H Ohkura T Fujioka Y Sumi K Yamamoto N Nakanishi R et al 2014 Bezaﬁbrate improves insulin resistance evaluated glucose clamp technique patients type 2 diabetes mellitus small scale clinical study Diabetology Metabolic Syndrome 6113 31 van Weijer T Havekes B Bilet L Hoeks J Sparks L Bosma M et al 2013 Effects bezaﬁbrate treatment patient carrier mutations PNPLA2 gene causing neutral lipid storage disease myopathy Circulation Research 112e51e54 32 Cariou B Hanf R LambertPorcheron S Zair Y Sauvinet V Noel B et al 2013 Dual peroxisome proliferatoractivated receptor alphadelta agonist GFT505 improves hepatic peripheral insulin sensitivity abdominally obese subjects Diabetes Care 362923e2930 33 Anwer T Sharma M Pillai KK Haque SE Alam MM Zaman MS 2007 Protective effect bezaﬁbrate streptozotocininduced oxidative stress toxicity rats Toxicology 229165e172 34 FernandesSantos C Evangelista Carneiro R Souza Mendonca L Barbosa Aguila M MandarimdeLacerda CA 2009 Rosiglitazone aggra vates nonalcoholic fatty pancreatic disease C57BL6 mice fed highfat highsucrose diet Pancreas 38e80e86 35 Cavaghan MK Ehrmann DA Byrne MM Polonsky KS 1997 Treatment oral antidiabetic agent troglitazone improves beta cell responses glucose subjects impaired glucose tolerance Journal Clinical Investigation 100530e537 36 Galgani JE Moro C Ravussin E 2008 Metabolic ﬂexibility insulin resistance American Journal Physiology Endocrinology Metabolism 295E1009eE1017 37 Franko A Hrabe De Angelis M Wiesner RJ 2015 Mitochondrial function dysfunction adaptation liver development diabetes In Han D Kaplowitz N Eds Mitochondria liver disease Abingdon UK CRC Press p 383e411 38 Franko A von KleistRetzow JC Bose M SanchezLasheras C Brodesser S Krut O et al 2012 Complete failure insulintransmitted signaling obesityinduced insulin resistance impairs respiratory chain function muscle Journal Molecular Medicine 901145e1160 39 Sleigh A RaymondBarker P Thackray K Porter D Hatunic M Vottero A et al 2011 Mitochondrial dysfunction patients primary Investigation 1212457e congenital 2461 insulin resistance Journal Clinical 40 van Weijer T Sparks LM Phielix E Meex RC van Herpen NA Hesselink MK et al 2013 Relationships mitochondrial function metabolic ﬂexibility type 2 diabetes mellitus PLoS One 8e51648 41 Hardwick JP OseiHyiaman D Wiland H Abdelmegeed MA Song BJ 2009 PPARRXR regulation fatty acid metabolism fatty acid omega hydroxylase CYP4 lipotoxicity isozymes fatty liver disease PPAR Research 2009952734 implications prevention 42 Samuel VT Shulman GI 2012 Mechanisms insulin resistance com mon threads missing links Cell 148852e871 43 Stefan N Fritsche A Schick F Haring HU 2016 Phenotypes pre diabetes stratiﬁcation cardiometabolic risk The Lancet Diabetes Endocrinology 4789e798 44 Martin PG Guillou H Lasserre F Dejean S Lan A Pascussi JM et al 2007 Novel aspects PPARalphamediated regulation lipid xenobiotic metabolism revealed nutrigenomic study Hepatology 45767e777 45 Stefan N Peter A Cegan A Staiger H Machann J Schick F et al 2008 Low hepatic stearoylCoA desaturase 1 activity associated fatty liver insulin resistance obese humans Diabetologia 51648e656 46 Peter A Weigert C Staiger H Machicao F Schick F Machann J et al 2009 Individual stearoylcoa desaturase 1 expression modulates endoplasmic reticulum stress inﬂammation human myotubes associated MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom 265 Original Article skeletal muscle lipid storage insulin sensitivity vivo Diabetes 581757e 1765 47 Silbernagel G Kovarova M Cegan A Machann J Schick F Lehmann R et al 2012 High hepatic SCD1 activity associated low liver fat content healthy subjects lipogenic diet Journal Clinical Endocrinology Metabolism 97E2288eE2292 48 Roden M 2016 The liver focus Diabetologia 591095e1097 49 Rosenson RS Wright RS Farkouh M Plutzky J 2012 Modulating peroxisome proliferatoractivated receptors therapeutic beneﬁt Biology clinical experience future prospects American Heart Journal 164672e680 50 Ratziu V Harrison SA Francque S Bedossa P Lehert P Serfaty L et al 2016 Elaﬁbranor agonist peroxisome proliferatoractivated receptoralpha delta induces resolution nonalcoholic steatohepatitis ﬁbrosis worsening Gastroenterology 150 1147e1159e1145 266 MOLECULAR METABOLISM 6 2017 256e266 cid1 2017 The Authors Published Elsevier GmbH This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 wwwmolecularmetabolismcom